Financials data is unavailable for this security.
View more
Year on year Biomarin Pharmaceutical Inc grew revenues 15.42% from 2.10bn to 2.42bn while net income improved 18.43% from 141.56m to 167.65m.
Gross margin | 80.07% |
---|---|
Net profit margin | 9.91% |
Operating margin | 9.15% |
Return on assets | 3.76% |
---|---|
Return on equity | 5.10% |
Return on investment | 4.29% |
More ▼
Cash flow in USDView more
In 2023, Biomarin Pharmaceutical Inc did not generate a significant amount of cash. However, the company earned 159.26m from its operations for a Cash Flow Margin of 6.58%. In addition the company used 111.24m on investing activities and also paid 18.73m in financing cash flows.
Cash flow per share | 1.86 |
---|---|
Price/Cash flow per share | 37.32 |
Book value per share | 27.77 |
---|---|
Tangible book value per share | 25.35 |
More ▼
Balance sheet in USDView more
Current ratio | 3.05 |
---|---|
Quick ratio | 1.95 |
Total debt/total equity | 0.206 |
---|---|
Total debt/total capital | 0.1708 |
More ▼